According to latest report, the global respiratory virus infection drugs market size valued at US$ 38.8 billion in 2020 and is predicted to hit around US$ 82.1 billion by 2030, expanding at a CAGR of 7.1% from 2021 to 2030.
According to latest report, the global respiratory virus infection drugs market size valued at US$ 38.8 billion in 2020 and is predicted to hit around US$ 82.1 billion by 2030, expanding at a CAGR of 7.1% from 2021 to 2030.
The viral respiratory infection affects the upper and lower respiratory tract. The respiratory virus infection is commonly caused by respiratory syncytial viruses, rhinoviruses, parainfluenza viruses, and influenza viruses. The global respiratory virus infection drugs market is driven by investments by key players to develop advanced therapeutics. Moreover, increase in acceptance of combination therapy to boost success rate of respiratory treatment presents significant opportunities to market players. These factors drive the global market.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38183
Rise in R&D Helps Address Low Solubility of Favipiravir in Aqueous Media
The respiratory virus infection drugs market is expected to surpass a value of US$ 82.1 Bn by the end of 2030. However, individuals are becoming increasingly aware about the disadvantages and side effects of influenza drugs, namely favipiravir and baloxavir. Pharma companies need to address low solubility of favipiravir in aqueous media, which may reduce its efficacy in vitro. This indicates that pharma companies need to increase their R&D activities to prevent adverse events of drugs.
Pharma companies are focusing on discoveries in influenza virus polymerase complex. It has been found that influenza viruses are severe human pathogens that pose as a persistent threat to public health. Hence, companies in the respiratory virus infection drugs market are capitalizing on this issue to increase their R&D in influenza virus polymerase complex.
Efficient Drug Delivery via Nanotechnology Offers Growth Prospects in Clinical Practice
Companies in the respiratory virus infection drugs market are increasing their focus in nanomaterials designed for antiviral drug delivery of adenovirus infection. This has become important, since respiratory virus infections have become a global health problem causing a significant amount of mortality and morbidity in individuals. Emerging drug resistance and constant viral replication have led to the demand for nanotechnology in antiviral therapies, as nanomaterials offer unique physic-chemical properties ideal for the treatment of adenovirus infection.
Different nanomaterials such as nanosheres, liposomes, nanoparticles, nanogels, and the likes hold promising potentials for efficacious drug administration in order to improve patient outcomes. Companies in the respiratory virus infection drugs market are innovating in nanosuspensions and nanoemulsions to enable drug delivery of unique antiviral agents with prospects in clinical practice.
AI-based Multi-program Approach Enables Development of Successful Candidates for Antibiotic Resistance
The COVID-19 pandemic has brought startups in the respiratory virus infection drugs market under great emphasis. For instance, Vir Biotechnology— a specialist in immune therapeutics, is leveraging the advantages of AI and ML in influenza drug development. It has been found that infectious diseases have increased resistance to antibiotics. Startups in the respiratory virus infection drugs market are capitalizing on this opportunity to integrate AI and ML in common cold and influenza drug development.
In order to broaden their revenue streams, the U.S.-based tech startups are working on solutions to address antibiotic resistance in certain strains of influenza A, SARS-CoV-2, and tuberculosis. They are adopting a multi-program and multi-platform approach to develop successful candidates in order to tackle antibiotic resistance. Manufacturers are innovating in antibody platforms and T cell platforms to isolate rare antibodies and use them to boost the immune system.
Report Highlights
In terms of drug type, the global respiratory virus infection drugs market has been classified into antibiotics, non-steroidal anti-inflammatory drugs (NSAIDS), cough suppressants, nasal decongestants, and others. Macrolides are a group of antibiotics considered promising treatment option for respiratory viral infections. This is likely to augment the segment.
Based on infection type, the global respiratory virus infection drugs market has been divided into respiratory syncytial virus (RSV) infection, influenza virus infection, parainfluenza virus infection, adenovirus infection, rhinovirus infection, and others. Adults with asthma, congestive heart failure, and COPD are at higher risk of suffering from respiratory syncytial virus infection. Hence, increase in the number of patients with these risk factors is projected to propel the segment.
In terms of route of administration, the global respiratory virus infection drugs market has been bifurcated into oral and parenteral. The preference of oral route due to better patient compliance, ease of administration, and versatility to accommodate various types of drug is anticipated to boost the growth of segment.
Based on mode of purchase, the global respiratory virus infection drugs market has been categorized into prescription-based drugs and over-the-counter drugs. Increase in awareness about the usage of antibiotics and standard guidelines for prescription antibiotics fuel the growth of the segment.
In terms of distribution channel, the global respiratory virus infection drugs market has been segregated into hospital pharmacies, drug stores, retail pharmacies, clinics, and others. Introduction of newer prescription products and availability of different dosage forms at hospital pharmacies are likely to drive the segment.
North America dominated the global respiratory virus infection drugs market in 2020, followed by Europe. North America accounted for a major share of the global respiratory virus infection drugs market in 2020. Presence of key players and focus on research & development are key factors projected to propel the respiratory virus infection drugs market in the region.
The respiratory virus infection drugs market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. The increase in investment by key players is expected to augment the respiratory virus infection drugs market in the region.
Key Players
Key players in the global respiratory virus infection drugs market include GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, Cipla, Inc., CHIESI Farmaceutici S.p.A., and Orion Corporation.
Market Segmentation
By Drug Type
-
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Cough Suppressants
- Nasal Decongestants
- Others
By Infection Type
-
- Respiratory Syncytial Virus (RSV) Infection
- Influenza Virus Infection
- Parainfluenza Virus Infection
- Adenovirus Infection
- Rhinovirus Infection
- Others
By Route of Administration
-
- Oral
- Parenteral
By Mode of Purchase
-
- Prescription-based Drugs
- Over-the-counter Drugs
By Distribution Channel
-
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Clinics
- Others
By Region
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38183
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333